Lung Transplantation for Advanced Bronchiectasis

Don Hayes; Keith C Meyer

doi:10.1055/s-0030-1249109

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2010; 31(2): 123-138
DOI: 10.1055/s-0030-1249109

Lung Transplantation for Advanced Bronchiectasis

Don Hayes¹ , Keith C. Meyer²

¹Departments of Pediatrics, Internal Medicine, and Surgery, University of Kentucky College of Medicine, Lexington, Kentucky
²Section of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

Abstract

ABSTRACT

Lung transplant (LT) can be successfully performed on patients with advanced bronchiectatic lung disease with subsequent good posttransplant quality of life and long-term outcome. Most of the data are derived from patients with cystic fibrosis (CF), but LT can be effective in patients with non-CF bronchiectasis as well. Despite the presence of chronic lower respiratory tract infection with bacterial pathogens in these patients pretransplant, posttransplant infections do not generally have significant impact on survival, although infection with antibiotic-resistant bacteria may complicate posttransplant management. Although benefit of LT for young children with CF is somewhat controversial, LT can clearly benefit older children and adults with advanced lung disease due to bronchiectasis. This article reviews indications (and contraindications) for LT, discusses particular problems that may arise posttransplant, and provides a rationale for referring patients with bronchiectasis for LT.

KEYWORDS

Cystic fibrosis - bronchiectasis - lung transplantation

Volltext

Referenzen

REFERENCES

1 Barker A F. Bronchiectasis. N Engl J Med. 2002; 346 1383-1393
2 O'Donnell A E. Bronchiectasis. Chest. 2008; 134 815-823
3 Loebinger M R, Wells A U, Hansell D M et al.. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J. 2009; 34 843-849
4 Courtney J M, Kelly M G, Watt A et al.. Quality of life and inflammation in exacerbations of bronchiectasis. Chron Respir Dis. 2008; 5 161-168
5 Feltrim M I, Rozanski A, Borges A C, Cardoso C A, Caramori M L, Pego-Fernandes P. The quality of life of patients on the lung transplantation waiting list. Transplant Proc. 2008; 40 819-821
6 Kerem B, Rommens J M, Buchanan J A et al.. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989; 245 1073-1080
7 Mueller C, Flotte T R. Gene therapy for cystic fibrosis. Clin Rev Allergy Immunol. 2008; 35 164-178
8 Ratjen F, Döring G. Cystic fibrosis. Lancet. 2003; 361 681-689
9 Tunney M M, Field T R, Moriarty T F et al.. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med. 2008; 177 995-1001
10 Worlitzsch D, Tarran R, Ulrich M et al.. Reduced oxygen concentrations in airway mucus contribute to the early and late pathogenesis of Pseudomonas aeruginosa cystic fibrosis airways infection. J Clin Invest. 2002; 109 317-325
11 Høiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros. 2005; 4(Suppl 2) 49-54
12 Christie J D, Edwards L B, Aurora P et al.. The registry of the International Society for Heart and Lung Transplantation: Twenty-Sixth Official Adult Lung and Heart–Lung Transplantation Report–2009. J Heart Lung Transplant. 2009; 28 1031-1049
13 Orens J B, Estenne M, Arcasoy S Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation et al. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006; 25 745-755
14 Bartz R R, Love R B, Leverson G E, Will L R, Welter D L, Meyer K C. Pre-transplant mechanical ventilation and outcome in patients with cystic fibrosis. J Heart Lung Transplant. 2003; 22 433-438
15 Kerem E, Reisman J, Corey M, Canny G J, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 1992; 326 1187-1191
16 Maurer J R, Frost A E, Estenne M, Higenbottam T, Glanville A R. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. J Heart Lung Transplant. 1998; 17 703-709
17 Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss C H, Aitken M L. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med. 2002; 166(12 Pt 1) 1550-1555
18 Rosenbluth D B, Wilson K, Ferkol T, Schuster D P. Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest. 2004; 126 412-419
19 Ellaffi M, Vinsonneau C, Coste J et al.. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am J Respir Crit Care Med. 2005; 171 158-164
20 Milla C E, Warwick W J. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest. 1998; 113 1230-1234
21 Doershuk C F, Stern R C. Timing of referral for lung transplantation for cystic fibrosis: overemphasis on FEV1 may adversely affect overall survival. Chest. 1999; 115 782-787
22 Augarten A, Akons H, Aviram M et al.. Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients. Pediatr Transplant. 2001; 5 339-342
23 Belkin R A, Henig N R, Singer L G et al.. Risk factors for death of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med. 2006; 173 659-666
24 Snell G I, Bennetts K, Bartolo J et al.. Body mass index as a predictor of survival in adults with cystic fibrosis referred for lung transplantation. J Heart Lung Transplant. 1998; 17 1097-1103
25 Stanchina M L, Tantisira K G, Aquino S L, Wain J C, Ginns L C. Association of lung perfusion disparity and mortality in patients with cystic fibrosis awaiting lung transplantation. J Heart Lung Transplant. 2002; 21 217-225
26 Tantisira K G, Systrom D M, Ginns L C. An elevated breathing reserve index at the lactate threshold is a predictor of mortality in patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med. 2002; 165 1629-1633
27 Liou T G, Adler F R, Cahill B C et al.. Survival effect of lung transplantation among patients with cystic fibrosis. JAMA. 2001; 286 2683-2689
28 Liou T G, Adler F R, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med. 2005; 171 1053-1059
29 Liou T G, Adler F R, Cox D R, Cahill B C. Lung transplantation and survival in children with cystic fibrosis. N Engl J Med. 2007; 357 2143-2152
30 Egan T M. Solid benefit of lung transplantation for some children with cystic fibrosis. Pediatr Transplant. 2008; 12 125-128
31 Sweet S C, Aurora P, Benden C International Pediatric Lung Transplant Collaborative et al. Lung transplantation and survival in children with cystic fibrosis: solid statistics—flawed interpretation. Pediatr Transplant. 2008; 12 129-136
32 Aurora P, Carby M, Sweet S. Selection of cystic fibrosis patients for lung transplantation. Curr Opin Pulm Med. 2008; 14 589-594
33 Ziedalski T M, Kao P N, Henig N R, Jacobs S S, Ruoss S J. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest. 2006; 130 995-1002
34 Hasan A, Corris P A, Healy M et al.. Bilateral sequential lung transplantation for end stage septic lung disease. Thorax. 1995; 50 565-566
35 Arcasoy S M, Kotloff R M. Lung transplantation. N Engl J Med. 1999; 340 1081-1091
36 Barlow C W, Robbins R C, Moon M R, Akindipe O, Theodore J, Reitz B A. Heart-lung versus double-lung transplantation for suppurative lung disease. J Thorac Cardiovasc Surg. 2000; 119 466-476
37 Rao J N, Forty J, Hasan A et al.. Bilateral lung transplant: the procedure of choice for end-stage septic lung disease. Transplant Proc. 2001; 33 1622-1623
38 Beirne P A, Banner N R, Khaghani A, Hodson M E, Yacoub M H. Lung transplantation for non-cystic fibrosis bronchiectasis: analysis of a 13-year experience. J Heart Lung Transplant. 2005; 24 1530-1535
39 Ikegami T, Sanchez E Q, Uemura T et al.. Liver transplantation for cystic fibrosis in adults. Surg Today. 2008; 38 26-29
40 Fridell J A, Bond G J, Mazariegos G V et al.. Liver transplantation in children with cystic fibrosis: a long-term longitudinal review of a single center's experience. J Pediatr Surg. 2003; 38 1152-1156
41 Milkiewicz P, Skiba G, Kelly D et al.. Transplantation for cystic fibrosis: outcome following early liver transplantation. J Gastroenterol Hepatol. 2002; 17 208-213
42 Forty J, Hasan A, Gould F K, Corris P A, Dark J H. Single lung transplantation with simultaneous contralateral pneumonectomy for cystic fibrosis. J Heart Lung Transplant. 1994; 13 727-730
43 Souilamas R, Mostafa A, Guillemain R, Boussaud V, Amrein C, Chevalier P. Single-lung transplantation for cystic fibrosis and metachronus pneumonectomy: case reports. Transplant Proc. 2008; 40 3594-3595
44 Wilson C B, Jones P W, O'Leary C J, Hansell D M, Cole P J, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J. 1997; 10 1754-1760
45 Martínez-García M A, Soler-Cataluña J J, Perpiñá-Tordera M, Román-Sánchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007; 132 1565-1572
46 Aris R M, Gilligan P H, Neuringer I P, Gott K K, Rea J, Yankaskas J R. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med. 1997; 155 1699-1704
47 Hadjiliadis D, Steele M P, Chaparro C et al.. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant. 2007; 26 834-838
48 De Soyza A, Archer L, Wardle J et al.. Pulmonary transplantation for cystic fibrosis: pre-transplant recipient characteristics in patients dying of peri-operative sepsis. J Heart Lung Transplant. 2003; 22 764-769
49 Dobbin C, Maley M, Harkness J et al.. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect. 2004; 56 277-282
50 Helmi M, Love R B, Welter D, Cornwell R D, Meyer K C. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest. 2003; 123 800-808
51 Nunley D R, Ohori P, Grgurich W F et al.. Pulmonary aspergillosis in cystic fibrosis lung transplant recipients. Chest. 1998; 114 1321-1329
52 Cimon B, Carrère J, Vinatier J F, Chazalette J P, Chabasse D, Bouchara J P. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2000; 19 53-56
53 Symoens F, Knoop C, Schrooyen M et al.. Disseminated Scedosporium apiospermum infection in a cystic fibrosis patient after double-lung transplantation. J Heart Lung Transplant. 2006; 25 603-607
54 Chernenko S M, Humar A, Hutcheon M et al.. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant. 2006; 25 1447-1455
55 Chalermskulrat W, Sood N, Neuringer I P et al.. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax. 2006; 61 507-513
56 Aris R M, Routh J C, LiPuma J J, Heath D G, Gilligan P H. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med. 2001; 164 2102-2106
57 Liou T G, Adler F R, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med. 2005; 171 1053-1059
58 Alexander B D, Petzold E W, Reller L B et al.. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant. 2008; 8 1025-1030
59 Murray S, Charbeneau J, Marshall B C, LiPuma J J. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med. 2008; 178 363-371
60 Snell G I, Levvey B J, Oto T et al.. Early lung transplantation success utilizing controlled donation after cardiac death donors. Am J Transplant. 2008; 8 1282-1289
61 Cypel M, Sato M, Yildirim E et al.. Initial experience with lung donation after cardiocirculatory death in Canada. J Heart Lung Transplant. 2009; 28 753-758
62 Starnes V A, Bowdish M E, Woo M S et al.. A decade of living lobar lung transplantation: recipient outcomes. J Thorac Cardiovasc Surg. 2004; 127 114-122
63 Rosbe K W, Jones D T, Rahbar R, Lahiri T, Auerbach A D. Endoscopic sinus surgery in cystic fibrosis: do patients benefit from surgery?. Int J Pediatr Otorhinolaryngol. 2001; 61 113-119
64 Holzmann D, Speich R, Kaufmann T et al.. Effects of sinus surgery in patients with cystic fibrosis after lung transplantation: a 10-year experience. Transplantation. 2004; 77 134-136
65 Leung M K, Rachakonda L, Weill D et al.. Effects of sinus surgery on lung transplantation outcomes in cystic fibrosis. Am J Rhinol. 2008; 22 192-196
66 Schwebel C, Pin I, Barnoud D et al.. Prevalence and consequences of nutritional depletion in lung transplant candidates. Eur Respir J. 2000; 16 1050-1055
67 Mozzillo E, Franzese A, Valerio G et al.. One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. Pediatr Diabetes. 2009; 10 162-167
68 Stringer D A, Sprigg A, Juodis E et al.. The association of cystic fibrosis, gastroesophageal reflux, and reduced pulmonary function. Can Assoc Radiol J. 1988; 39 100-102
69 Brodzicki J, Trawińska-Bartnicka M, Korzon M. Frequency, consequences and pharmacological treatment of gastroesophageal reflux in children with cystic fibrosis. Med Sci Monit. 2002; 8 CR529-CR537
70 Benden C, Aurora P, Curry J, Whitmore P, Priestley L, Elliott M J. High prevalence of gastroesophageal reflux in children after lung transplantation. Pediatr Pulmonol. 2005; 40 68-71
71 Blondeau K, Mertens V, Vanaudenaerde B A et al.. Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. Eur Respir J. 2008; 31 707-713
72 Palmer S M, Miralles A P, Howell D N, Brazer S R, Tapson V F, Davis R D. Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation. Chest. 2000; 118 1214-1217
73 D'Ovidio F, Mura M, Ridsdale R et al.. The effect of reflux and bile acid aspiration on the lung allograft and its surfactant and innate immunity molecules SP-A and SP-D. Am J Transplant. 2006; 6 1930-1938
74 Dellon E S, Morgan D R, Mohanty S P, Davis K, Aris R M. High incidence of gastric bezoars in cystic fibrosis patients after lung transplantation. Transplantation. 2006; 81 1141-1146
75 Morton J R, Ansari N, Glanville A R, Meagher A P, Lord R V. Distal intestinal obstruction syndrome (DIOS) in patients with cystic fibrosis after lung transplantation. J Gastrointest Surg. 2009; 13 1448-1453
76 Yates B, Murphy D M, Fisher A J et al.. Pseudomembranous colitis in four patients with cystic fibrosis following lung transplantation. Thorax. 2007; 62 554-556
77 Bhardwaj S, Canlas K, Kahi C et al.. Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood. J Clin Gastroenterol. 2009; , Jun 11. [Epub ahead of print]
78 Nash K L, Allison M E, McKeon D et al.. A single centre experience of liver disease in adults with cystic fibrosis 1995-2006. J Cyst Fibros. 2008; 7 252-257
79 Klima L D, Kowdley K V, Lewis S L, Wood D E, Aitken M L. Successful lung transplantation in spite of cystic fibrosis-associated liver disease: a case series. J Heart Lung Transplant. 1997; 16 934-938
80 King S J, Topliss D J, Kotsimbos T et al.. Reduced bone density in cystic fibrosis: DeltaF508 mutation is an independent risk factor. Eur Respir J. 2005; 25 54-61
81 Quattrucci S, Rolla M, Cimino G et al.. Lung transplantation for cystic fibrosis: 6-year follow-up. J Cyst Fibros. 2005; 4 107-114
82 Spahr J E, Love R B, Francois M, Radford K, Meyer K C. Lung transplantation for cystic fibrosis: current concepts and one center's experience. J Cyst Fibros. 2007; 6 334-350
83 Meyer K C. The Role of Neutrophils in Transplantation: Immunobiology of Organ Transplantation. New York; Kluwer/Plenum 2004: 493-507
84 Krenn K, Klepetko W, Taghavi S, Paulus P, Aharinejad S. Vascular endothelial growth factor increases pulmonary vascular permeability in cystic fibrosis patients undergoing lung transplantation. Eur J Cardiothorac Surg. 2007; 32 35-41
85 Dupuis R E, Sredzienski E S. Tobramycin pharmacokinetics in patients with cystic fibrosis preceding and following lung transplantation. Ther Drug Monit. 1999; 21 161-165
86 Saint-Marcoux F, Knoop C, Debord J et al.. Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. Clin Pharmacokinet. 2005; 44 1317-1328
87 Knoop C, Vervier I, Thiry P et al.. Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions. Transplantation. 2003; 76 683-688
88 Berge M, Guillemain R, Boussaud V et al.. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl Infect Dis. 2009; 11 211-219
89 Cadena J, Levine D J, Angel L F et al.. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant. 2009; 9 2085-2091
90 Veith F J, Kamholz S L, Mollenkopf F P, Montefusco C M. Lung transplantation 1983. Transplantation. 1983; 35 271-278
91 Date H, Trulock E P, Arcidi J M, Sundaresan S, Cooper J D, Patterson G A. Improved airway healing after lung transplantation: an analysis of 348 bronchial anastomoses. J Thorac Cardiovasc Surg. 1995; 110 1424-1432, discussion 1432–1433
92 Weder W, Inci I, Korom S et al.. Airway complications after lung transplantation: risk factors, prevention and outcome. Eur J Cardiothorac Surg. 2009; 35 293-298, discussion 298
93 Moreno P, Alvarez A, Algar F J et al.. Incidence, management and clinical outcomes of patients with airway complications following lung transplantation. Eur J Cardiothorac Surg. 2008; 34 1198-1205
94 Vos R, Vanaudenaerde B M, Geudens N, Dupont L J, Van Raemdonck D E, Verleden G M. Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation?. Eur Respir J. 2008; 31 1037-1045
95 Bonvillain R W, Valentine V G, Lombard G, LaPlace S, Dhillon G, Wang G. Post-operative infections in cystic fibrosis and non-cystic fibrosis patients after lung transplantation. J Heart Lung Transplant. 2007; 26 890-897
96 Gottlieb J, Mattner F, Weissbrodt H et al.. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir Med. 2009; 103 743-749
97 Sarahrudi K, Estenne M, Corris P et al.. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg. 2004; 127 1126-1132
98 Gerhardt S G, McDyer J F, Girgis R E, Conte J V, Yang S C, Orens J B. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med. 2003; 168 121-125
99 Verleden G M, Dupont L J. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2004; 77 1465-1467
100 Yates B, Murphy D M, Forrest I A et al.. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2005; 172 772-775
101 Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2008; 85 36-41
102 Mertens V, Blondeau K, Pauwels A et al.. Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients. Dig Dis Sci. 2009; 54 972-979
103 Egan T M, Detterbeck F C, Mill M R et al.. Improved results of lung transplantation for patients with cystic fibrosis. J Thorac Cardiovasc Surg. 1995; 109 224-234, discussion 234–235
104 Williams T J, Patterson G A, McClean P A, Zamel N, Maurer J R. Maximal exercise testing in single and double lung transplant recipients. Am Rev Respir Dis. 1992; 145 101-105
105 Levy R D, Ernst P, Levine S M et al.. Exercise performance after lung transplantation. J Heart Lung Transplant. 1993; 12(1 Pt 1) 27-33
106 Egan T M, Detterbeck F C, Mill M R et al.. Long term results of lung transplantation for cystic fibrosis. Eur J Cardiothorac Surg. 2002; 22 602-609
107 Vermeulen K M, van der Bij W, Erasmus M E, Duiverman E J, Koëter G H, TenVergert E M. Improved quality of life after lung transplantation in individuals with cystic fibrosis. Pediatr Pulmonol. 2004; 37 419-426
108 Choong C K, Meyers B F. Quality of life after lung transplantation. Thorac Surg Clin. 2004; 14 385-407
109 Smeritschnig B, Jaksch P, Kocher A et al.. Quality of life after lung transplantation: a cross-sectional study. J Heart Lung Transplant. 2005; 24 474-480

Keith C MeyerM.D. M.S.

Section of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health

K4/910 CSC, 600 Highland Ave., Madison, WI 53792-9988

eMail: kcm@medicine.wisc.edu